Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: First-year results of the randomised controlled TARA study

Annals of the Rheumatic Diseases

Volumn 78, Issue 6, 2019, Pages 746-753

  Van Mulligen, Elise ^a   De Jong, Pascal Hendrik Pieter ^a   Kuijper, Tjallingius Martijn ^b   Van Der Ven, Myrthe ^a   Appels, Cathelijne ^c   Bijkerk, Casper ^d   Harbers, Joop B ^e   De Man, Yael ^f   Molenaar, T H Esmeralda ^g   Tchetverikov, Ilja ^h   Goekoop Ruiterman, Yvonne P M ⁱ   Van Zeben, Jende ^j   Hazes, Johanna M W ^a   Weel, Angelique E A M ^b   Luime, Jolanda J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d REINIER DE GRAAF HOSPITAL   (Netherlands)

^e Franciscus ziekenhuis   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g GROENE HART HOSPITAL   (Netherlands)

^h ALBERT SCHWEITZER HOSPITAL   (Netherlands)

ⁱ HAGA HOSPITAL   (Netherlands)

^j Sint Franciscus Gasthuis   (Netherlands)

more..

Author keywords

anti TNF therapy; csdmards; drug withdrawal; rheumatoid arthritis; tapering

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HUMAN; LARGE CELL LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE; SKIN BRUISING; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; PATIENT-REPORTED OUTCOME; RADIOGRAPHY; REMISSION; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; RADIOGRAPHY; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR INHIBITORS;

EID: 85064003323     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214970     Document Type: Article

References (34)

1. Kuijper TM, Luime JJ, de Jong PHP, et al. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Ann Rheum Dis 2016;75:2119-23.
2. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet 2010;376:1094-108.
3. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
4. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
5. Fautrel B, Den Broeder AA. De-intensifying treatment in established rheumatoid arthritis (rA): why, how, when and in whom can DMARDs be tapered? Best Pract Res Clin Rheumatol 2015;29:550-65.
6. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled retro study. Ann Rheum Dis 2016;75:45-51.
7. Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 2016;68:1810-7.
8. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016;75:1428-37.
9. Kuijper TM, Lamers-Karnebeek FBG, Jacobs JWG, et al. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol 2015;42:2012-22.
10. Edwards CJ, Fautrel B, Schulze-Koops H, et al. Dosing down with biologic therapies: a systematic review and clinicians' perspective. Rheumatology 2017;56:1847-56.
11. van Herwaarden N, den Broeder AA, Jacobs W, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 2014;9.
12. van Vollenhoven RF, Ostergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75:52-8.
13. van Herwaarden N, van der Maas A, Minten MJM, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015;350:h1389.
14. Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: spacing of TNF-blocker injections in rheumatoid arthritis study). Ann Rheum Dis 2016;75:59-67.
15. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (preserve): a randomised controlled trial. Lancet 2013;381:918-29.
16. Siegert CE, Vleming LJ, Vandenbroucke JP, et al. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3:305-9.
17. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
18. McHorney CA, Ware JE, Raczek AE. The mos 36-Item short-form health Survey (SF-36): II. psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
19. Ware JE, Sherbourne CD. The mos 36-item short-form health Survey (SF-36). I. conceptual framework and item selection. Med Care 1992;30:473-83.
20. van der Heijde D. How to read radiographs according to the Sharp/van Der Heijde method. J Rheumatol 2000;27:261-3.
21. van Tuyl LHD, van der Heijde D, Knol DL, et al. Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. Ann Rheum Dis 2014;73:391-5.
22. van der Heijde D, Simon L, Smolen J, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002;47:215-8.
23. Nederlandse Vereniging voor Reumatologie. NVR Richtlijnen medicijnen: biologicals, 2014. Available: https://www. nvr. nl/ wp- content/ uploads/ 2014/ 11/ NVR- Medicijnen- Update- Biologicals- richtlijn- 23-6-2014. pdf [Accessed Jul 2018].
24. Nederlandse Vereniging voor Reumatologie. NVR Richtlijnen medicijnen: sulfazalazine, 2002. Available: https://www. nvr. nl/ wp- content/ uploads/ 2014/ 11/ NVR- Medicijnenrichtlijn- Sulfasalazine- 2002. pdf [Accessed Jul 2018].
25. Nederlandse Vereniging voor Reumatologie. NVR Richtlijnen medicijnen: methotrexaat, 2011. Available: https://www. nvr. nl/ wp- content/ uploads/ 2014/ 11/ NVRMedicijnen- MTX- richtlijn- 2009- update- 2011. pdf [Accessed Jul 2018].
26. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by remicade in rA) study. Ann Rheum Dis 2010;69:1286-91.
27. Saleem B, Brown AK, Keen H, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with diseasemodifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 2009;60:1915-22.
28. Lagana B, Picchianti Diamanti A, Ferlito C, et al. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption. Int J Immunopathol Pharmacol 2009;22:447-54.
29. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
30. Gotzsche PC, Hansen M, Stoltenberg M, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 1996;25:194-9.
31. Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the best study. Ann Rheum Dis 2011;70:315-9.
32. Allaart CF, Lems WF, Huizinga TWJ. The best way of withdrawing biologic agents. Clin Exp Rheumatol 2013;31(4 Suppl 78):S14-18.
33. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review Informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
34. Van Mulligen E, Weel A, Kuijper TM, et al. OP0113 Gradual tapering tnf blockers versus conventional synthetic dmards in patients with rheumatoid arthritis in sustained remission: first year results of the randomised controlled tara-study [abstract]. Ann Rheum Dis 2018;77.